Use of nepafenac (Nevanac®)in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections

Keyphrases

• Intravitreal Anti-vascular Endothelial Growth Factor Injection 100%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 100%
• Exudative Macular Degeneration 100%
• Nepafenac 100%
• Visual Acuity 80%
• Optical Coherence Tomography 80%
• Intravitreal Ranibizumab 40%
• Subretinal Fluid 40%
• Pigment Epithelial Detachment 40%
• Intraretinal Cysts 40%
• Response to Therapy 20%
• Statistical Analysis 20%
• Long Follow-up 20%
• Thickness Measurement 20%
• Student's T-test 20%
• Maintenance Therapy 20%
• Consecutive Case Series 20%
• Patients Included 20%
• Clinical Exam 20%
• Central Foveal Thickness 20%
• Quantitative Optical Coherence Tomography 20%
• Pinhole 20%
• Monthly Means 20%

Medicine and Dentistry

• Wet Macular Degeneration 100%
• Endothelial Cell Growth Factor 100%
• Nepafenac 100%
• Optical Coherence Tomography 83%
• Visual Acuity 66%
• Retinal Detachment 33%
• Subretinal Fluid 33%
• Prospective Study 16%
• Intravitreal Administration 16%
• Bevacizumab 16%
• Student T Test 16%
• Maintenance Therapy 16%
• Consecutive Case Series 16%
• Ranibizumab 16%

Nursing and Health Professions

• Wet Macular Degeneration 100%
• Endothelial Cell Growth Factor 100%
• Nepafenac 100%
• Optical Coherence Tomography 83%
• Visual Acuity 66%
• Retina Detachment 33%
• Subretinal Fluid 33%
• Intravitreal Drug Administration 16%
• Student T Test 16%
• Maintenance Therapy 16%
• Bevacizumab 16%
• Ranibizumab 16%
• Efficacy 16%